1. Home
  2. IPSC vs ENTX Comparison

IPSC vs ENTX Comparison

Compare IPSC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • ENTX
  • Stock Information
  • Founded
  • IPSC 2019
  • ENTX 2010
  • Country
  • IPSC United States
  • ENTX Israel
  • Employees
  • IPSC N/A
  • ENTX N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IPSC Health Care
  • ENTX Health Care
  • Exchange
  • IPSC Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • IPSC 58.1M
  • ENTX 69.6M
  • IPO Year
  • IPSC 2021
  • ENTX 2018
  • Fundamental
  • Price
  • IPSC $0.54
  • ENTX $1.79
  • Analyst Decision
  • IPSC Strong Buy
  • ENTX Strong Buy
  • Analyst Count
  • IPSC 5
  • ENTX 1
  • Target Price
  • IPSC $3.67
  • ENTX $10.00
  • AVG Volume (30 Days)
  • IPSC 551.0K
  • ENTX 30.9K
  • Earning Date
  • IPSC 05-08-2025
  • ENTX 05-09-2025
  • Dividend Yield
  • IPSC N/A
  • ENTX N/A
  • EPS Growth
  • IPSC N/A
  • ENTX N/A
  • EPS
  • IPSC N/A
  • ENTX N/A
  • Revenue
  • IPSC $6,589,000.00
  • ENTX $181,000.00
  • Revenue This Year
  • IPSC $833.10
  • ENTX N/A
  • Revenue Next Year
  • IPSC N/A
  • ENTX N/A
  • P/E Ratio
  • IPSC N/A
  • ENTX N/A
  • Revenue Growth
  • IPSC 194.81
  • ENTX N/A
  • 52 Week Low
  • IPSC $0.34
  • ENTX $1.41
  • 52 Week High
  • IPSC $3.70
  • ENTX $2.79
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 53.48
  • ENTX 49.59
  • Support Level
  • IPSC $0.34
  • ENTX $1.50
  • Resistance Level
  • IPSC $0.54
  • ENTX $1.84
  • Average True Range (ATR)
  • IPSC 0.05
  • ENTX 0.11
  • MACD
  • IPSC 0.02
  • ENTX 0.03
  • Stochastic Oscillator
  • IPSC 93.95
  • ENTX 85.50

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: